Candidiasis - Global Pipeline Review, H2 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 22, 2019--
The “Candidiasis - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Candidiasis (Infectious Disease) pipeline guide also reviews key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 2, 27, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 8 molecules, respectively.
Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2isxhf
View source version on businesswire.com:https://www.businesswire.com/news/home/20191122005347/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 11/22/2019 10:08 AM/DISC: 11/22/2019 10:08 AM